Anthony Hodsman

Summary

Affiliation: University of Western Ontario
Country: Canada

Publications

  1. ncbi request reprint Evaluation of an osteoporosis self-referral program to enhance management outcomes
    A B Hodsman
    Department of Medicine and Lawson Research Institute, University of Western Ontario, London, Ontario, Canada
    J Clin Densitom 7:77-84. 2004
  2. ncbi request reprint Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
    Anthony B Hodsman
    Department of Medicine, Lawson Health Research Institute, University of Western Ontario, London, Ontario, Canada N6A 4V2
    J Clin Endocrinol Metab 88:5212-20. 2003
  3. doi request reprint 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program
    Anthony B Hodsman
    Osteoporosis Program, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Arch Intern Med 168:2261-7. 2008
  4. pmc Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date
    Anthony B Hodsman
    Department of Medicine, University of Western Ontario, London
    CMAJ 166:1426-30. 2002
  5. ncbi request reprint Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated?
    A B Hodsman
    University of Western Ontario and Division of Nephrology, London Health Sciences Centre, Canada
    Perit Dial Int 21:S247-55. 2001
  6. pmc Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis
    Anthony Hodsman
    Division of Nephrology, University of Western Ontario and St Joseph s Health Centre, London, Ont
    CMAJ 175:48. 2006
  7. ncbi request reprint Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
  8. pmc Optimizing care in osteoporosis: the Canadian quality circle project
    George Ioannidis
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    BMC Musculoskelet Disord 9:130. 2008
  9. pmc The utilization of appropriate osteoporosis medications improves following a multifaceted educational intervention: the Canadian quality circle project (CQC)
    George Ioannidis
    Department of Medicine, McMaster University, Hamilton, Canada
    BMC Med Educ 9:54. 2009
  10. doi request reprint Fracture risk in living kidney donors: a matched cohort study
    Amit X Garg
    Division of Nephrology, Department of Medicine, Western University, London, Canada
    Am J Kidney Dis 59:770-6. 2012

Detail Information

Publications29

  1. ncbi request reprint Evaluation of an osteoporosis self-referral program to enhance management outcomes
    A B Hodsman
    Department of Medicine and Lawson Research Institute, University of Western Ontario, London, Ontario, Canada
    J Clin Densitom 7:77-84. 2004
    ..01). The self-referral program positively impacted decisions women made about preventing osteoporosis, particularly if they considered themselves at higher risk...
  2. ncbi request reprint Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
    Anthony B Hodsman
    Department of Medicine, Lawson Health Research Institute, University of Western Ontario, London, Ontario, Canada N6A 4V2
    J Clin Endocrinol Metab 88:5212-20. 2003
    ..Dose-related incidences of transient hypercalcemia occurred, but only one patient (100-microg group) was withdrawn because of repeated hypercalcemia. Thus, full-length PTH was efficacious and safe over 12 months...
  3. doi request reprint 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program
    Anthony B Hodsman
    Osteoporosis Program, Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Arch Intern Med 168:2261-7. 2008
    ..Wrist fractures are the most prevalent type of fracture occurring in postmenopausal women. We sought to contrast the probability of recurrent osteoporotic fractures after a primary wrist fracture with other important primary fracture sites...
  4. pmc Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date
    Anthony B Hodsman
    Department of Medicine, University of Western Ontario, London
    CMAJ 166:1426-30. 2002
  5. ncbi request reprint Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated?
    A B Hodsman
    University of Western Ontario and Division of Nephrology, London Health Sciences Centre, Canada
    Perit Dial Int 21:S247-55. 2001
    ....
  6. pmc Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis
    Anthony Hodsman
    Division of Nephrology, University of Western Ontario and St Joseph s Health Centre, London, Ont
    CMAJ 175:48. 2006
  7. ncbi request reprint Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
    ..At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued...
  8. pmc Optimizing care in osteoporosis: the Canadian quality circle project
    George Ioannidis
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    BMC Musculoskelet Disord 9:130. 2008
    ....
  9. pmc The utilization of appropriate osteoporosis medications improves following a multifaceted educational intervention: the Canadian quality circle project (CQC)
    George Ioannidis
    Department of Medicine, McMaster University, Hamilton, Canada
    BMC Med Educ 9:54. 2009
    ..However, appropriate therapy utilization of the disease remains suboptimal. Thus, the objective of the study was to change physicians' therapy administration behavior in accordance with the Osteoporosis Canada 2002 guidelines...
  10. doi request reprint Fracture risk in living kidney donors: a matched cohort study
    Amit X Garg
    Division of Nephrology, Department of Medicine, Western University, London, Canada
    Am J Kidney Dis 59:770-6. 2012
    ..Living kidney donors lose 50% of their renal mass and show changes in calcium homeostasis. We studied whether living kidney donation increases the risk of fragility fracture...
  11. pmc Parathyroid hormone for the treatment of osteoporosis: a systematic review
    Ann Cranney
    Department of Medicine, University of Ottawa, Ottawa, Ont
    CMAJ 175:52-9. 2006
    ....
  12. doi request reprint Family physicians' personal and practice characteristics that are associated with improved utilization of bone mineral density testing and osteoporosis medication prescribing
    George Ioannidis
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Popul Health Manag 12:131-8. 2009
    ..The education of both clinicians and policy makers regarding these new insights may translate to enhanced individual practices and an improved overall health care system to optimize the environment for managing osteoporosis...
  13. ncbi request reprint Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment
    Kerry Siminoski
    Department of Radiology and Diagnostic Imaging and Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Canada
    J Clin Densitom 10:120-3. 2007
    ..We propose that an individual's absolute fracture risk category should be the basis for deciding on treatment and frequency of BMD monitoring...
  14. ncbi request reprint Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis
    A B Hodsman
    Department of Medicine and Lawson Research Institute, University of Western Ontario, London, ON, Canada
    Bone 27:311-8. 2000
    ....
  15. ncbi request reprint Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans
    L J Fraher
    Department of Medicine, The Lawson Research Institute, St Joseph s Health Center, University of Western Ontario, London, Canada
    J Clin Endocrinol Metab 84:2739-43. 1999
    ..However, at the doses employed, it does not increase serum calcium, is a weaker stimulator of the 25-hydroxyvitamin D-1alpha-hydroxylase, and does not induce rapid bone resorption...
  16. ncbi request reprint Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat
    A B Hodsman
    Department of Medicine, Lawson Research Institute, University of Western Ontario, London, Canada
    Bone 24:451-5. 1999
    ....
  17. doi request reprint Oral bisphosphonate use in the elderly is not associated with acute kidney injury
    Andrew W Y Shih
    Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Kidney Int 82:903-8. 2012
    ..03), and no significant differences in other outcomes or in subgroups of patients with baseline chronic kidney disease. Thus, in this older population-based cohort, oral bisphosphonate use was not associated with acute kidney injury...
  18. doi request reprint Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?
    A Ross Morton
    Kingston General Hospital, Ontario, Canada
    Hemodial Int 14:200-10. 2010
    ..The therapeutic grid is a valid tool and may help guide therapeutic decisions, quality control initiatives, and patient counseling. http://www.ukidney.com/bone-and-mineral-metabolism-resource...
  19. ncbi request reprint Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: association with serum-induced cell proliferation
    P H Watson
    Department of Medicine, University of Western Ontario and The Lawson Research Institute, London, Canada
    Bone 26:221-5. 2000
    ..These data suggest an important role for the PTHR in the nucleus of MC3T3-E1 cells at the time of DNA synthesis and mitosis...
  20. ncbi request reprint Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat
    P H Watson
    Department of Medicine, The University of Western Ontario and The Lawson Research Institute, St Joseph s Health Centre, London, Canada
    Bone 24:89-94. 1999
    ....
  21. ncbi request reprint Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions
    William D Leslie
    University of Manitoba, Winnipeg, Manitoba, Canada, and McGuire Veterans Affairs Medical Center, Richmond, VA, USA
    J Clin Densitom 9:22-30. 2006
    ..quot; T-scores are preferred and the WHO classification is applicable for postmenopausal women and men age 50 and older. These Official Positions, rationale and evidence are discussed in the following report...
  22. pmc Management of osteoporosis in men: an update and case example
    Aliya A Khan
    Division of Endocrinology and Geriatrics, Department of Medicine, McMaster University, Hamilton, Ont
    CMAJ 176:345-8. 2007
    ..The current paper supplements that guideline and provides a review and synthesis of the current literature on the diagnosis and management of osteoporosis in men...
  23. ncbi request reprint A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    Jean Jacques Body
    Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    J Clin Endocrinol Metab 87:4528-35. 2002
    ..In conclusion, teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate...
  24. ncbi request reprint Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment
    Wojciech P Olszynski
    Department of Medicine, University of Saskatchewan, Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada
    Clin Ther 26:15-28. 2004
    ..Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life...
  25. ncbi request reprint Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients
    Neil C Boudville
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA, Australia
    Nephrol Dial Transplant 21:2621-4. 2006
    ....
  26. ncbi request reprint Bone strength: the whole is greater than the sum of its parts
    K Shawn Davison
    Clinical Research Scientist, Department of Medicine, Laval University, Sainte Foy, Quebec, Canada
    Semin Arthritis Rheum 36:22-31. 2006
    ..To summarize the current knowledge regarding the various determinants of bone strength...
  27. ncbi request reprint The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future
    K Shawn Davison
    Clinical Research Scientist, Department of Medicine, Laval University, Sainte Foy, Quebec, Canada
    Semin Arthritis Rheum 36:10-21. 2006
    ..To summarize the current knowledge regarding the impact of the most common antifracture medications on the various determinants of bone strength...
  28. ncbi request reprint Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium
    Robert Lindsay
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    J Bone Miner Res 22:495-502. 2007
    ..Enhanced bone formation was associated with an increase in osteoblast apoptosis...
  29. ncbi request reprint Standards for performing DXA in individuals with secondary causes of osteoporosis
    Aliya A Khan
    Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
    J Clin Densitom 9:47-57. 2006
    ..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis...